RE:RE:Khiron Boosts European Expansion With Key Executive AppointmHere's a snippet from Ted Ohashi's weekly newsletter regarding Khiron:
LATE BREAKING NEWS: Khiron Life Sciences announces the appointment of Tejinder Virk as President, Khiron Europe and Franziska Katterback, Chief Legal Officer, Khiron Europe. Both Tejinder (who I have met and am acquainted with and Franziska have strong professional backgrounds. But what I found most interesting is Tejinder was previously Deputy Managing Director, Europe for Canopy Growth and Franziska served as Director of Legal for Canopy Growth’s European operations. This announcement reminds me that around nine months ago, I was talking with Alvaro Torres, Chief Executive Officer of Khiron and the person most responsible for the operational aspects of KHRN’s growth. He said to me, “We are thinking about an adjustment to our Business Plan that you might find quite audacious.” A while later I leaned that Khiron was thinking about expanding into Europe in a big way using their operations in Latin America as the base. This was at a time when the large, Canadian Licensed Producers were using their North American base of operations to support expansion into Europe. I thought of that conversation when KHRN moved into Uruguay. I thought about it again when Mercosur, the Latin American trading block of which Uruguay is a member entered into a trade agreement with the European Union. I’m thinking about it now as Tejinder and Franziska join Khiron as President of Khiron Europe and Chief Legal officer, Khiron Europe, respectively. I think this is just the beginning of Khiron’s presence in Europe. Chris Naprawa, President of Khiron Life Sciences (TSXV: KHRN) spoke at Canaccord Genuity’s (CG) 39th Annual Growth Conference in Boston. Growth Conference in Boston. The following are excerpts from his talk from a CG report following the presentation. “…Naprawa reiterated Khiron’s focus on patients and brands and the company’s primary objective of securing a million patients. In Colombia, medical CBD sales are expected to begin this quarter, following the initial harvest of CBD cannabis. Extracts will be delivered to patients individually as specifically prepared formulations and Khiron is currently working through the final commercialization steps. Furthermore, Mr. Naprawa stated that the company expects to start THC medical sales later this year, pending the receipt of a THC quota. Khiron also continues to pursue insurance coverage. Company remains bullish on the Mexican and Brazilian markets. Specifically, Mr. Naprawa highlighted the recreational potential in Mexico and its strong positioning through its Dixie joint venture (JV). This week, Dixie announced a major JV with Arizona, the top-ranking iced tea beverage maker in the US, which management believes validates Dixie's product platform. Another area management is excited about is CBD pet care products, which it expects could be commercialized by late 2019 or early 2020.” Canaccord Genuity has a price target of $6.75 per share for KHRN that closed at $2.08 per share. That makes KHRN potentially more than a triple in CG’s estimation.